|
|
Volumn 14, Issue 5, 2014, Pages e161-e163
|
|
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma
a
|
|
Author keywords
Mitogen activated protein kinase; Mutation; Refractory myeloma; V600E; Vemurafenib
|
|
Indexed keywords
ALBUMIN;
B RAF KINASE;
BETA 2 MICROGLOBULIN;
BORTEZOMIB;
BRCA1 PROTEIN;
CARFILZOMIB;
CISPLATIN;
CYCLIN DEPENDENT KINASE INHIBITOR 2C;
CYCLOPHOSPHAMIDE;
DEXAMETHASONE;
DOXORUBICIN;
ETOPOSIDE;
IKBKE PROTEIN;
IMMUNOGLOBULIN G;
IMMUNOGLOBULIN G KAPPA;
LACTATE DEHYDROGENASE;
LENALIDOMIDE;
MELPHALAN;
NARCOTIC AGENT;
NOTCH2 RECEPTOR;
POMALIDOMIDE;
PROTEIN MCL 1;
PROTEIN MDMX;
RETINOBLASTOMA PROTEIN;
UNCLASSIFIED DRUG;
VEMURAFENIB;
ANTINEOPLASTIC AGENT;
BORONIC ACID DERIVATIVE;
BRAF PROTEIN, HUMAN;
INDOLE DERIVATIVE;
PROTEIN KINASE INHIBITOR;
PYRAZINE DERIVATIVE;
SULFONAMIDE;
THALIDOMIDE;
TUMOR PROTEIN;
ADULT;
AGED;
ALBUMIN BLOOD LEVEL;
ARTICLE;
AUTOLOGOUS STEM CELL TRANSPLANTATION;
BONE BIOPSY;
BONE MARROW BIOPSY;
BONE RADIOGRAPHY;
CANCER GROWTH;
CANCER PALLIATIVE THERAPY;
CANCER RADIOTHERAPY;
CANCER RECURRENCE;
CANCER RESISTANCE;
CANCER STAGING;
CASE REPORT;
COMPUTER ASSISTED TOMOGRAPHY;
DERMATITIS;
DRUG SUBSTITUTION;
DRUG TOLERABILITY;
FUNCTIONAL STATUS;
GENE DELETION;
GENE MUTATION;
GENETIC CODE;
HUMAN;
IMMUNOGLOBULIN BLOOD LEVEL;
INTRON;
LACTATE DEHYDROGENASE BLOOD LEVEL;
MAINTENANCE THERAPY;
MALE;
METAPHASE;
MIDDLE AGED;
MULTIPLE CYCLE TREATMENT;
MULTIPLE MYELOMA;
POSITRON EMISSION TOMOGRAPHY;
SQUAMOUS CELL CARCINOMA;
TREATMENT DURATION;
TREATMENT RESPONSE;
TUMOR BIOPSY;
ANALOGS AND DERIVATIVES;
AUTOTRANSPLANTATION;
DISEASE COURSE;
FATALITY;
GENETICS;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
MEDIASTINAL NEOPLASMS;
MISSENSE MUTATION;
MULTIMODALITY CANCER THERAPY;
OSTEOLYSIS;
PALLIATIVE THERAPY;
PATHOLOGY;
PLASMACYTOMA;
POINT MUTATION;
RADIOTHERAPY;
REMISSION;
SALVAGE THERAPY;
SECOND CANCER;
TREATMENT OUTCOME;
AGED;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BORONIC ACIDS;
CARCINOMA, SQUAMOUS CELL;
COMBINED MODALITY THERAPY;
DEXAMETHASONE;
DISEASE PROGRESSION;
FATAL OUTCOME;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
INDOLES;
MALE;
MEDIASTINAL NEOPLASMS;
MIDDLE AGED;
MULTIPLE MYELOMA;
MUTATION, MISSENSE;
NEOPLASM PROTEINS;
NEOPLASMS, SECOND PRIMARY;
OSTEOLYSIS;
PALLIATIVE CARE;
PLASMACYTOMA;
POINT MUTATION;
PROTEIN KINASE INHIBITORS;
PROTO-ONCOGENE PROTEINS B-RAF;
PYRAZINES;
REMISSION INDUCTION;
SALVAGE THERAPY;
SULFONAMIDES;
THALIDOMIDE;
TRANSPLANTATION, AUTOLOGOUS;
TREATMENT OUTCOME;
|
|
EID: 84908897547
PISSN: 21522650
EISSN: 21522669
Source Type: Journal
DOI: 10.1016/j.clml.2014.06.004 Document Type: Article |
|
Times cited : (41)
|
|
References (6)
|
